High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.
INTRODUCTION
Intensive chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is one therapeutic option for a subset of eligible patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL). 1 A previous European Blood and Marrow Transplantation Society survey reported on 1880 patients with HL and 6000 patients with NHL who received auto-HSCT in 2013. 2 Auto-HSCT has been increasingly performed over the years and has become one of the most common treatment approaches for aggressive forms of lymphoma. 2 Auto-HSCT was not widely adopted as a first-line treatment for high-risk patients with diffuse large B-cell lymphoma in the rituximab era, and this treatment has consequently not been recommended outside of clinical trials. However, auto-HSCT has recognized benefits for chemosensitive patients presenting with initially chemotherapy-refractory disease or those who have relapsed after first-line therapy and are eligible for intensive therapy. 3, 4 For mantle cell lymphoma, auto-HSCT has demonstrated benefits associated with response and survival. 5 For follicular lymphoma, auto-HSCT is not recommended as a consolidation first-line treatment because of its excessive toxicity and lack of benefit for overall survival (OS). 6 However, this therapeutic approach is used in patients with sensitive relapse. 7, 8 The role of auto-HSCT for the treatment of peripheral T-cell lymphoma is not clearly established because of the rarity of this disease and the absence of randomized studies. 9 Nevertheless, a Nordic team recently reported a high PFS rate of 44% in a phase II prospective study of patients who underwent transplant as a first response. 10 When selecting high-dose therapy, both long-term treatment efficacy and potential short-and long-term toxicities must be considered. The toxicity of TBI in the setting of auto-HSCT has progressively decreased its use because of the risk of acute leukemia, secondary myelodysplastic syndromes and cumulative organ toxicity in the case of previous radiation, primarily in HL. 11, 12 The BEAM regimen, which utilizes a combination of carmustine (BCNU), etoposide, cytarabine and melphalan, is the most frequently used conditioning regimen before auto-transplantation. [2] [3] [4] However, BCNU is in short supply and has a high cost, necessitating the identification of conditioning alternatives. In the absence of prospective randomized studies comparing different types of conditioning, we reviewed the data from the most important and largest published studies to propose recommendations for alternative chemotherapies to be used as conditioning regimens before auto-HSCT.
METHODOLOGY
The French Society of Bone Marrow Transplantation and Cellular Therapy (SFGMTC) and the Lymphoma Study Association (LYSA) established a collaborative work group. The group met to discuss BEAM conditioning alternatives for auto-transplantation for lymphoma. An extensive literature review was performed focusing on high-dose therapy in the setting of lymphoma. Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; members were responsible for reviewing and synthesizing all the data and writing the manuscript. The final document was sent to readers who provided their opinion on the text before submission for review by the scientific boards of the Lymphoma Study Association and the French Society of Bone Marrow Transplantation and Cellular Therapy.
OVERVIEW OF CARMUSTINE-BASED CONDITIONING REGIMENS
Several types of BCNU-based conditioning regimens have been developed (Supplementary Table 1 ). Unfortunately, none of these regimens has been compared in prospective or randomized studies. Each regimen involves a combination of two to four drugs, including alkylating agents. The CBV (cyclophosphamide (Cy), BCNU and etoposide), BEAM (BCNU, etoposide, aracytine and melphalan) and BEAC regimens (BCNU, etoposide, aracytine and Cy) are the most frequently used. These treatments are generally associated with a post-transplant complete response rate of 60-85% and 2-to 5-year disease-free survival rates that vary from 34 to 60% with variable toxicities depending on the types and doses of drugs used.
Toxicities
In a 2006 study published by a Spanish team, the toxicities of CBV and BEAM were retrospectively compared in 113 patients. 13 The results showed comparable hematological toxicities between the two conditioning regimens. However, higher non-hematological toxicities, including mucositis (63% versus 34%, P = 0.004), renal failure (12% versus 0%, P = 0.02), sinusoidal obstruction syndrome (7% versus 0%, P = 0.04) and pulmonary toxicities, were noted in the CBV group. Treatment-related mortality (TRM) was primarily infection-related, with rates of 5% for BEAM and 24% for CBV (P = 0.02). The excessive toxicity of CBV was associated with the higher total BCNU dose in the CBV regimen (800 mg/m 2 ) versus the BEAM regimen (300 mg/m 2 ). The total etoposide dose was comparable between the two regimens (750 versus 800 mg/m 2 ). Another more recent analysis evaluated 4917 patients (NHL = 3905, HL = 1012) who received auto-HSCT after high-dose therapy with BEAM (n = 1730), CBV (n = 1853; CBV low (BCNU = 300 mg/m 2 ) and CBV high (BCNU = 450 mg/m 2 )), BuCy (busulfan (Bu) and Cy, n = 789) or TBI-based (n = 545) treatment. This analysis reported comparable 1-year TRM rates between the groups (ranging from 4 to 8%), but pulmonary complications were high in the CBV high and TBI-based regimens. 
Platelet recovery time BM = 24 (10-250) CBV = 14 (9-58) BEAM = 13.5 (7-31) Abbreviations: BEAM = BCNU+etoposide+aracytine+melphalan; BM = bone marrow; BuCyE = busulfan+cyclophosphamide+etoposide; BuEM = busulfan +etoposide+melphalan; CBV = cyclophosphamide+BCNU+VP16 (etoposide); DFS = disease-free survival; EFS = event-free survival; Mo = month; NS = not significant; OS = overall survival; PMN = polymorphonuclear; PSC = peripheral stem cell. Sinusoidal obstruction syndrome was reported in the studies by Kim et al. 82 (two for BEAM and one for BuCyE) and Sakellari et al. 88 (in one case after BEAM). In the study by Sakellari et al., 88 sepsis was significantly higher following BuEM than BEAM (P = 0.006).
The BEAC (BCNU, etoposide, aracytine and Cy) combination is less frequently used, especially in France, and the toxicity of this regimen is higher than that of the BEAM combination. For BEAC, the TRM (infectious, cardiac and pulmonary) is high at~23%. 13 Thus, BEAM remains the most used conditioning regimen with acceptable toxicity and low TRM.
13 Table 1 summarizes the main toxicities associated with BEAM (particularly BCNU).
Efficacy Interestingly, type of conditioning influences both incidence of relapse and survival in certain disease subcategories.
The risk of progression or relapse was lower in patients with HL who received BuCy (P = 0.006) or TBI-based conditioning (P = 0.024) compared to BEAM.
The risk of relapse or progression was higher in patients with mantle cell lymphoma who received CBV high compared with CBV low (P = 0.005). TBI was associated with a decreased risk of relapse compared to BEAM (P = 0.004), with no impact on survival (P = 0.95).
The OS of patients with follicular lymphoma was significantly higher for those treated with CBV low versus BEAM and CBV high (P = 0.006 and P = 0.002, respectively).
Patients with diffuse large B-cell lymphoma treated with high doses of BCNU (CBV high ) exhibited an inferior survival rate compared with patients treated with BEAM or CBV low (P = 0.001 and P = 0.003, respectively). A higher conditioning TRM rate and notably elevated doses of BCNU (4350 mg/m 2 ) can explain these differences.
ALTERNATIVES TO BCNU IN CONDITIONING REGIMENS
Lomustine-based conditioning regimen Sharme et al.
14 proposed the LEAM regimen, which replaces BCNU with oral lomustine, as an alternative to BEAM. Data on this regimen are scarce, and its toxicity was comparable to BEAM in a historical, retrospective comparative study.
Bendamustine-based conditioning regimen: BeAM Bendamustine is a bifunctional, cytotoxic compound with structural similarities to alkylating agents and purine analogs. 15 The pharmacokinetics of a single dose are equivalent to those of several successive doses. 16, 17 The maximum dose concentration is attained at the end of a 1-h perfusion. The half-life is estimated at 40 min, and there is a low probability of accumulation after repeated daily doses. Renal elimination of the drug is minimal and estimated at 3% of the total administered dose. Bendamustine exhibited high antitumor activity in preclinical 18 and clinical studies, 19, 20 and this activity was independent of cellular resistance to typical alkylating agents. 15 The limiting toxicities reported in phase I monotherapy studies were thrombocytopenia (320 mg/m 2 ), cardiac arrhythmia (320 mg/m 2 ) and digestive complications. Kidney failure was not reported. [21] [22] [23] [24] Bendamustine is effective against indolent lymphomas, 25,26 chronic lymphocytic leukemia, mantle cell lymphoma, 27 large B-cell lymphomas, 28 peripheral T-cell lymphomas, 29, 30 HLs [31] [32] [33] and multiple myelomas. [34] [35] [36] The doses used are 50-180 mg/m 2 on days 1 and 2 or a total dose of 100-360 mg/m 2 in a single intravenous perfusion over 30-60 min every 21-28 days. Digestive disorders and increased infectious toxicities were associated with higher doses. 19, 23, 37 In current practice, the recommended monotherapy doses, or the doses recommended in combination with rituximab, for lymphomas and multiple myelomas vary from 60 to 120 mg/m 2 .
38
Bendamustine use in high-dose chemotherapy. An Italian group recently reported the first use of bendamustine as part of a conditioning regimen. Visani et al. reported that the maximum tolerated dose of bendamustine was not attained in nine patients on day 6 to day 7 when bendamustine was used in combination with a fixed dose of aracytine (400 mg/m 2 /day, day 2 to day 5), etoposide (200 mg/m 2 /day, day 2 to day 5) and melphalan (140 mg/m 2 , day 1). 39 The extension phase II study included 34 patients, to whom bendamustine was administered at a dose of 200 mg/m 2 /day on day 6 and day 7 (total dose of 400 mg/m 2 ) as Table 2 . Main toxicities of bendamustine-based conditioning regimens
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Martin et al. Abbreviations: ALCL = anaplastic large-cell lymphoma; FL = follicular lymphoma; HL = Hodgkin lymphoma; LBCL = large B-cell lymphoma; MCL = mantle cell lymphoma; NA = non-applicable; OS = overall survival; PMN = polymorphonuclear; PTCL = periphery T-cell lymphoma.
a Martin reported 39 serious adverse events. Atrial fibrillation was reported in 10 and 8% of patients in the studies by Garciaz and Noesslinger et al., 41, 44 , respectively. Need for ICU management was reported in 28% of patients in the study by Garciaz et al. 44 3-Year PFS and OD were 72% in the study by Visani et al. b Resolved in all cases (in Martin, three patients already had a kidney failure episode).
an intravenous perfusion for an hour in 500 ml of 0.9% physiological serum. 39 The conditioning was well tolerated, and there was no procedure-related mortality. The median times to platelet count ⩾ 20 G/L and polymorphonuclear (PMN) count ⩾ 0.5 G/L were 13 and 10 days, respectively. Non-hematological toxicities were dominated by grade 3/4 mucositis (26%) and grade 2-4 gastroenteritis (35%). No grade 3/4 renal, hepatic, cardiac or pulmonary toxicity was observed. 39, 40 Several reports on the use of a bendamustine-based conditioning regimen before auto-HSCT were recently published as abstracts (Table 2 and Supplementary Table 2) 41-43 and a journal letter. 44 Bendamustine was used at 200 mg/m 2 /day for two successive days in these studies, except for the study reported by Martino et al., 42 in which bendamustine was used at a dose of 100 mg/m 2 in combination with melphalan for patients with multiple myeloma. Toxicities were comparable between the different studies ( Table 2 ). The most frequent grade 3/4 toxicities were sepsis (9-20%), fever (16-100%), mucositis (18-28%), gastrointestinal toxicities (4-26%) and kidney failure (31%).
On the basis of its activity in a wide range of hematologic diseases, bendamustine is an attractive drug, and it may have a major role in conditioning regimens. However, data on its usage remain limited and are derived from samples with limited numbers of patients, providing a narrow perspective on toxicities. Therefore, its use should remain within the framework of clinical trials.
Thiotepa-based conditioning regimens Thiotepa, primarily via its active metabolite TEPA, exhibits alkylating action similar to that of nitrogen mustards. This agent has been used as an alternative to classic conditioning regimens based on carmustine to improve the tolerance/effectiveness relationship [45] [46] [47] [48] for patients with NHL [49] [50] [51] or multiple myeloma (Table 3a and Table 3b ). [52] [53] [54] In adults, thiotepa is preferentially indicated for the treatment of lymphoid malignancies with central nervous system (CNS) localization. This preference is because of its ability to cross the blood-brain barrier and its potential to be combined with other cytotoxic drugs, such as Bu and Cy (thiotepa, busulfan, cyclophosphamide (TBC). 55 A recent meta-analysis highlighted the effectiveness of TBC in patients with primary or secondary CNS lymphoma, and the French reference center for primary oculocerebral lymphoma group recommends thiotepa-based conditioning in these settings. 56, 57 In 2001, Gutierrez-Delgado et al. 50 published a comparative study examining thiotepa, Bu and melphalan (TBM) conditioning (n = 130) to TBI/CyE conditioning (n = 221). There was no significant difference in efficacy or toxicity between the two treatment regimens. Furthermore, OS, event-free survival (EFS) and relapse rates at 5 years were 42%, 34% and 42%, respectively, for TBM and 44%, 32% and 49%, respectively, for TBI/Cy-E. TRM rates were comparable, ranging from 21 and 16%. Zaucha et al. 58 observed comparable results. However, this type of conditioning regimen was not superior to high-dose melphalan alone for multiple myelomas. 52 The TBM combination was better than CBV, BEAM or Cyclo-TBI for patients with HL, 45 but these results were not confirmed in other studies. 47 Thiotepa has also been used in combination with etoposide, cytarabine and melphalan (TEAM; Supplementary Table 3) . One study compared the results from TEAM conditioning to those from BEAM conditioning in 114 patients with malignant large B-cell lymphoma (LBCL), follicular lymphoma or HL. The 3-year PFS, OS and relapse rates were 64%, 82% and 33%, respectively, for TEAM and 60%, 80% and 40%, respectively, for BEAM. There was no significant difference between the two groups in toxicity. 59 Another study evaluated the efficacy and toxicity of the TEAM protocol in 120 (HL = 51; NHL = 69) patients with relapsed or Table 3a . Main toxicities of thiotepa-based conditioning regimens Dimopoulos et al. 54 Anagnostopoulos et al. 52 Bains et al. 45 Ganguly et al.
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Conditioning regimens for lymphoma G Damaj et al refractory disease. The overall and complete response rates were 84.8% and 82.3%, respectively, and the TRM rate was 1%. 60 The efficacy/tolerance relationship favored BEAM or high-dose melphalan, which appeared less toxic than TBC or TBM.
52,58 TBM was as toxic as TBI/Cy-E. 47 The TRM rate varied between 0 and 29% for conditioning regimens that combined at least thiotepa and Bu. Age 460 years was a predictive factor for TRM. 49 Notably, thiotepa-based conditioning without Bu (TC or TECa) was better tolerated, with no TRM 46, [61] [62] [63] [64] (Table 3a and Table 3b ). Grade 3-4 non-hematological toxicities were mostly gastrointestinal, such as diarrhea (38%) and mucositis (100%). Febrile neutropenia was reported in 14-90% of cases, and infections (bacterial, fungal and viral) were reported in 10-45% of cases, which may justify the use of antiviral prophylaxis. Cases of sinusoidal obstruction syndrome (SOS) of the liver were reported exclusively with TBM, 45, 50, 51, 58 and cutaneous toxicities are the most-reported side effect of thiotepa. Other non-hematological toxicities, including renal, pulmonary, cardiac and hepatic toxicity, are rarer. These toxicities are related to age ⩾ 55-60 years. 49, 53 Approximately 900 patients, many with diffuse large B-cell lymphoma with CNS involvement, have been treated with TBC (thiotepa (250 mg/m 2 /day) for 3 days, Bu (3.2 mg/kg/day) for 3 days and Cy (60 mg/kg/day) for 2 days is the most frequently used regimen).
BU-BASED CONDITIONING
Bu is an alkylating agent that damages DNA 65 synergistically with nucleoside analogs in lymphoma cell lineages. 66 Developed in the 1980s, orally administered Bu 62 was initially widely used in conditioning for allogeneic HSCT and, to a lesser degree, for auto-HSCT. Intravenous Bu 67 has the best bioavailability in vivo with few toxicities (for example, mucositis and SOS) and high efficacy in patients with lymphoma. 69, 70 A Bu-based conditioning regimen was used in double or triple combination with melphalan-like BuCyM, 71 etoposide 51 or Cy 72 or both, similar to Bu-Cy-etoposide (BuCyE) 73 (Table 4, Supplementary Table 4) . Notably, most Bu-based conditioning studies were retrospective, included a low number of patients and exhibited histological heterogeneity with different prognoses, which hinders the drawing of firm and definitive conclusions.
Copelan et al. 74 evaluated 382 patients with lymphoma who received an auto-transplant after conditioning with BuCyE (oral Bu) and reported grade 3-4 organ toxicities in 3.7% of the group. The most important side effect was hepatic toxicity, which consisted of SOS in 2.9% of cases. Disease management was more successful for indolent lymphoma (PFS 56.4%) than for aggressive forms (PFS 43.7%) of the disease.
Hepatic toxicity has been reported in several studies. One retrospective study of 132 patients (53% LBCL) treated with Bu-based conditioning (IV form in 82% of cases) observed SOS in 7.6% of patients. The two predictive factors for SOS occurrence were use of a Bu-Thiotepa combination (odds ratio (OR) 8.8; P = 0.003) and serum ferritin ⩾ 950 μg/mL (OR 8.8; P = 0.003). 75 A recent study by Shin et al. 76 compared the results of 56 patients with LBCL receiving Bu-based conditioning with those from patients receiving BEAM or BEAC. The OS was longer for the Bu group than the BCNU group, with 2-year OS rates of 70% and 46%, respectively. 77 BuCyE was also evaluated in combination with 90 Yttrium tiuxetan in 19 patients in relapse or with refractory LBCL. Three-year OS and EFS rates were 52.6% and 26.3%, respectively, in a population that previously received two lines of treatment. 78 The TBM regimen was also compared with TBI/Cy/E in patients with NHL. Five-year OS and EFS rates were not significantly different between TBI/Cy/E and TBM (44% and 32%, respectively; 42% and 34%, respectively). The corresponding TRM values were 16 and 21% for patients who had already undergone radiotherapy (N = 59 50 ). Omuro et al. 93 Welch et al. 94 Cote et al. 95 Gopal et al. 100% across the studies. Kidney failure was reported in three patients across studies. Skin rash was reported in 8 and 12% of patients (Zaucha et al.
58
; Omuro et al.
93
).
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Thirty-seven patients with indolent follicular lymphoma received fludarabine and Bu-based conditioning regimens prospectively in a phase II study. The PFS was 46%, and the OS was 72%. No TRM was reported. 79 Ahn et al. 80 evaluated the efficacy of BuCyE (Bu 3.2 mg/kg/day × 3 days IV) in 31 patients with T-cell lymphoma. OS and PFS were both 64.6%. The TRM (mainly SOS) was reported at 9.8%.
Bu was also evaluated in tandem with auto-HSCT in high-risk patients with HL. The first conditioning combined Cy/carmustine/ etoposide/mitoxantrone followed by a second conditioning that included Bu (12 mg/kg), cytarabine (6 g/m 2 ) and melphalan (140 mg/m 2 ; BAM-6). 81 To date, no data regarding the role of BAM conditioning in the context of single auto-HSCT have been reported.
Two recent retrospective studies evaluated IV Bu-based conditioning. The first study evaluated 65 patients with NHL who received an autologous transplant between 2002 and 2008. . Patient characteristics were comparable between the two groups. Hematologic recovery (polymorphonuclear (PMN) 40.5 G/L and platelets 420 G/L) was significantly more rapid in the BEAM group than in the BuCyE group (P = 0.007 and P = 0.041, respectively). Gastrointestinal complications, such as nausea, were significantly more common with BuCyE (P = 0.025). TRM was nonsignificantly higher with BuCyE (9.1%) compared with BEAM (4.3%). EFS and OS rates were comparable between the two treatments.
Another study was conducted after BCNU became scarce in . In contrast to the preceding study on Bu-based conditioning, granulocyte and platelet recovery times were longer with BuEM than BEAM (P = 0.001 and P = 0.025, respectively). Grade 1-2 infectious complications (P = 0.006), grade 3-4 mucositis (6.8% versus 46%, Po 0.001) and digestive complications were more frequent in the BuEM group than in the BEAM group. Surprisingly, erythrocyte and platelet transfusion rates were lower (P o0.001) in the BuEM group. In terms of efficacy, the authors reported an improved 2-year OS for BuEM compared with BEAM in patients with HL (96.2% versus 77.3%; P = 0.05) and a better PFS with BuEM for HL compared with NHL (85.1% versus 41%, P = 0.017).
Using a historical comparison of consecutive studies, MD Anderson evaluated gemcitabine, Bu and melphalan conditioning in patients with refractory or relapsed HL. Despite the higher percentage of patients who were PET-positive at the time of auto-HSCT, the EFS and OS were significantly higher than those for Bu/M (57% and 82% versus 33% and 52%, respectively). Notably, Bu administration was based on a single extemporaneous pharmacokinetic analysis that was not reproducible in all centers.
Intravenous Bu in a single daily dose (3.2 mg/kg/day over 3 h) is approved in France for use in allo-HSCT for reduced-intensity conditioning; this includes the combination of Bu and fludarabine. Several recent studies have investigated the use of intravenous Bu as a single daily dose in patients undergoing auto-HSCT, and a tolerance that seems equivalent to standard fractionated doses has been observed. The first study evaluated 47 children with Burkitt lymphoma or other solid tumors. Bu was used with melphalan and thiotepa or high-dose Cy. The authors of this study reported a 0% TRM rate with no cases of SOS after a median follow-up of 18 months. Shin et al. 76 Sakellari et al. 88 Dean et al. 69 Kim et al. 82 Stewart et al. 79 Ahn et al. 80 Nieto et al. 26 (19) 12 (54) 1 (3) 31 (100) 133 (100) More than first line 32 (100) 50 (100) 110 (81) 10 (46) 36 (97) 0 (0) Age, median (range) Mucositis and gastroenteritis were reported at rates of 6-54% and 6-18%, respectively.
Conditioning regimens for lymphoma G Damaj et al were equivalent. The TRM rate for the combination was 4% versus 2% for melphalan alone. SOS was not reported. Nieto et al. 77 used a single dose of Bu in combination with Gem and melphalan in 133 HL, 47 NHL and 7 myeloma cases. Toxicity appeared equivalent to other conditioning treatments, except for cutaneous toxicity, which was related to gemcitabine dose. However, Bu was used under the control of daily monitoring and adaptation in accordance with area under the curve analysis. Nieto et al. 77 reported another study comparing GemBuM with BEAM and BuM (Bu administered as a single dose). Toxicity seemed equivalent between regimens; however, there were better survival results with GemBuM. 86 
CONCLUSION
In the absence of prospective comparative studies, it is difficult to recommend one conditioning regimen (Supplementary Table 5 ) over another because there is a lack of an acceptable level of scientific evidence. The choice of a conditioning regimen could not be evaluated based on efficacy because of the heterogeneity of the studied population and the disease types included in past cohorts, which have different prognostic factors.
Nevertheless, we propose that choosing a regimen should be based on conditioning toxicity, known efficacy of certain drugs, tumor location, drug approval by competing authorities, such as for thiotepa and Busulfan, and drug cost. Finally, the necessity of prioritizing participation in ongoing clinical trials should not be overlooked.
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